Home / Oncology (page 30)

Oncology

ASCO and Tempus Collaborate to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study

ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) — The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to …

Read More »

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

FLORHAM PARK, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) — Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced median overall survival (mOS) in Cohorts 1-4 of the company’s ongoing Phase 1 clinical trial evaluating CLR …

Read More »

bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

CAMBRIDGE, Mass. & SAN DIEGO–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Inhibrx, Inc. (Inhibrx) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Inhibrx’s proprietary single domain antibody (sdAb) platform to multiple cancer targets. The …

Read More »

Lilly to Pay $8 Billion to Acquire Loxo Oncology

Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be the …

Read More »

Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

PARIS and TARRYTOWN, NY – January 7, 2019 – Sanofi (EURONEXT: SAN, NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was scheduled to end in approximately mid-2020, and this revision provides for ongoing collaborative development of two clinical-stage …

Read More »

QIAGEN Acquires N-of-One, Expanding Its Clinical Bioinformatics Capabilities in Molecular Oncology Decision Support

Redwood City, California, and Hilden, Germany, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One …

Read More »

Adaptive Biotechnologies and Genentech Enter Worldwide Collaboration and License Agreement to Develop Personalized Cellular Therapies for Treatment of Cancer

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers. The collaboration will …

Read More »

C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-Based Medicines with Roche

WATERTOWN, Mass.–(BUSINESS WIRE)–C4 Therapeutics (C4T) announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology. “We are excited to see our partnership with Roche evolve and further accelerate our efforts to bring degrader-based medicines into the clinic,” …

Read More »

Onxeo Announces Identification of Predictive Biomarkers for AsiDNA, its First-in-Class DNA Damage Response Inhibitor

PARIS–(BUSINESS WIRE)–Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the identification of predictive biomarkers for AsiDNA™, its first-in-class non-targeted DNA Damage Response (DDR) inhibitor, which enables …

Read More »

Personal Genome Diagnostics Collaborates with Merck on Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today reported that its 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (NSCLC) (KEYNOTE-495). This study will investigate the …

Read More »